Clinical Trial

Effects of DHA-NAT on Postprandial Lipidaemia in Healthy Male Subjects

Study acronym: FEAST
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of DHA-NAT (C22:6 N-acyl taurine, an endogenous metabolite derived from the omega-3 fatty acid, docosahexaenoic acid) on postprandial plasma triglyceride levels following a high-fat meal.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-11; most recent amendment 2025-03-25.
Status change: Recruiting → Active, Not Recruiting 2023-11-16
Trial Details
NCT Number NCT05953064
Lead Sponsor University Hospital, Gentofte, Copenhagen
Conditions Hypertriglyceridemia
Enrollment 20 participants
Start Date 2023-01-01
Primary Completion 2023-10-31 (estimated)
Study Completion 2025-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-30